Exelixis's oncology ambitions on track with European Cometriq approval
This article was originally published in Scrip
The European Commission has approved Exelixis's Cometriq (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC). The product is licensed to Swedish Orphan Biovitrum (Sobi) in Europe. The decision follows a positive recommendation from the EMA's CHMP in December (scripintelligence.com, 20 December 2014).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.